Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2012 Nov;122(11):3857-9.
doi: 10.1172/JCI65929. Epub 2012 Oct 15.

Amazing IL-9: revealing a new function for an "old" cytokine

Affiliations
Comment

Amazing IL-9: revealing a new function for an "old" cytokine

Edgar Schmitt et al. J Clin Invest. 2012 Nov.

Abstract

The incidence of melanoma - the most aggressive form of skin cancer - is dramatically increasing, while the development of innovative therapeutic strategies continues to be challenging, especially due to a lack of knowledge about the molecular mechanisms underlying melanoma progression as well as antitumor immunity. In this issue of the JCI, Yong Lu and colleagues report a central role for Th9 cells in antitumor immunity.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Effector functions of Th9 cells in antitumor immune responses.
Th9-derived IL-9 can have direct antitumor effects or can indirectly influence tumor growth by altering immune responses. IL-9 induces the production of CCL20 in lung epithelial cells, which mediates the recruitment of CCR6-expressing DCs and CD8+ CTLs. In addition, the MEA of IL-9 could further potentiate the induction of an adaptive antitumor immune response by providing mast cell–derived IL-1β and TNF-α. IL-9R, IL-9 receptor.

Comment on

  • Th9 cells promote antitumor immune responses in vivo.
    Lu Y, Hong S, Li H, Park J, Hong B, Wang L, Zheng Y, Liu Z, Xu J, He J, Yang J, Qian J, Yi Q. Lu Y, et al. J Clin Invest. 2012 Nov;122(11):4160-71. doi: 10.1172/JCI65459. Epub 2012 Oct 15. J Clin Invest. 2012. PMID: 23064366 Free PMC article.

References

    1. Dougan M, Dranoff G. Immune therapy for cancer. Annu Rev Immunol. 2009;27:83–117. doi: 10.1146/annurev.immunol.021908.132544. - DOI - PubMed
    1. Leek RD, et al. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res. 1996;56(20):4625–4629. - PubMed
    1. Ribatti D, et al. Tumor vascularity and tryptase-positive mast cells correlate with a poor prognosis in melanoma. Eur J Clin Invest. 2003;33(5):420–425. doi: 10.1046/j.1365-2362.2003.01152.x. - DOI - PubMed
    1. Topalian SL, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454. doi: 10.1056/NEJMoa1200690. - DOI - PMC - PubMed
    1. Hodi FS, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi: 10.1056/NEJMoa1003466. - DOI - PMC - PubMed

MeSH terms